Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Savara ( (SVRA) ).
Savara Inc. has updated its corporate presentation, highlighting its ongoing efforts to develop MOLBREEVI, a potential treatment for autoimmune PAP, which currently has no approved drugs in the U.S. or Europe. The announcement underscores the company’s commitment to addressing the unmet medical needs of patients with this rare and chronic lung disease, which is currently treated through an invasive procedure known as whole lung lavage.
The most recent analyst rating on (SVRA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Savara stock, see the SVRA Stock Forecast page.
Spark’s Take on SVRA Stock
According to Spark, TipRanks’ AI Analyst, SVRA is a Neutral.
Savara’s stock score reflects a company in the developmental stage, with significant financial risks due to its lack of revenue and ongoing cash burn. However, a strong balance sheet and recent financing developments provide some stability. Technical indicators suggest short-term positive momentum, but valuation remains challenging with a negative P/E ratio. The recent loan agreement is a positive step, potentially facilitating future growth and commercialization efforts.
To see Spark’s full report on SVRA stock, click here.
More about Savara
Savara Inc. operates in the pharmaceutical industry, focusing on developing new therapies for rare respiratory diseases. The company is currently working on MOLBREEVI, an investigational product for autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease.
Average Trading Volume: 1,210,564
Technical Sentiment Signal: Hold
Current Market Cap: $566.9M
Learn more about SVRA stock on TipRanks’ Stock Analysis page.